Journal article
Adjuvant ovarian suppression in premenopausal breast cancer
PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, HR Bonnefoi, MA Climent, GA Da Prada, HJ Burstein, S Martino, NE Davidson, CE Geyer, BA Walley, R Coleman, P Kerbrat, S Buchholz, JN Ingle, EPM Winer, M Rabaglio-Poretti Show all
New England Journal of Medicine | Published : 2015
Abstract
BACKGROUND Suppression of ovarian estrogen production reduces the recurrence of hormonereceptor- positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.METHODS We randomly assigned 3066 premenopausal women, stratified according to prior receipt or nonreceipt of chemotherapy, to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression. The primary analysis tested the hypothesis that tamoxifen plus ovarian suppression would improve disease-free survival, as compared with tamoxifen alone. In the primary analysis, 46.7% of the patients had not received chemotherapy previously, and 53.3% had received ..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Funded by Pfizer and others; SOFT ClinicalTrials.gov number, NCT00066690.